Klaria Pharma
Klaria Interim Report Q3 2024
Third quarter of 2024
The group in total
- Net sales 0.0 MSEK (0.6 MSEK)
- Other income 0.0 MSEK (0.0 MSEK)
- R&D expenses for the quarter amounted to 1 MSEK (7.4 MSEK)
- Profit after tax amounted to -7.9 MSEK (-10.8 MSEK)
- Earnings per share for the quarter amounted to -0.06 SEK (-0.10 SEK)
- Cash flow from operating activities amounted to -3.8 MSEK (-7.3 MSEK)
- Liquid assets on the balance sheet date amounted to 0.5 MSEK (2.3 MSEK)
- Equity as of September 30 amounted to 12.9 MSEK (50.7 MSEK)
The period January- September 2024
The group in total
- Net sales 0.0 MSEK (7.1 MSEK)
- Other income 0.0 MSEK (0.2 MSEK)
- R&D expenses for the quarter amounted to 2.5 MSEK (23.0 MSEK)
- Profit after tax amounted to -32.2 MSEK (-26.3 MSEK)
- Earnings per share for the period amounted to -0.26 SEK (-0.27 SEK)
- Cash flow from operating activities amounted to -13.2 MSEK (-18.6 MSEK)
| Datum | 2024-11-21, kl 15:00 |
| Källa | Cision |
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 15 000 unika besökare per månad. Vår discord har över 6000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!